4results about How to "Reduce cardiotoxicity" patented technology

This invention provides a pharmaceutical composition containing hezemibrate and an HMG-CoA reductase inhibitor, and may further include one or more excipients selected from calcium carbonate, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, sodium lauryl sulfate, polysorbate, croscarmellose sodium, crospovidone, microcrystalline cellulose, povidone, hydroxypropyl cellulose, lactose, pregelatinized starch, magnesium stearate, and talc. This composition can be formulated into various dosage forms, exhibiting good formulation stability and controllable quality.

This invention relates to the fields of biomedical engineering and drug delivery technology, specifically disclosing a novel targeted drug delivery system based on rosehip extracellular vesicles, comprising: preparing rosehip-derived extracellular vesicles; preparing drug-loaded vesicles; and preparing targeted modified drug-loaded vesicles. This invention utilizes the specific downregulation of stem cell-related pathways by rosehip components, while simultaneously leveraging doxorubicin to kill conventional tumor cells, forming a complementary therapeutic mechanism to fundamentally reduce the risk of tumor recurrence. The phenylboronic acid group of DSPE-PEG-PBA specifically recognizes sialic acid overexpressed on the surface of tumor cells, significantly increasing drug accumulation in tumor tissues while reducing distribution in normal tissues. By leveraging the natural biocompatibility and low immunogenicity of RHNVs, combined with the long-circulating properties of the PEG chain, systemic toxicity is minimized while ensuring delivery efficiency, particularly reducing the cardiotoxicity and bone marrow suppression of doxorubicin.

This invention provides a benzothiadiazine 1,1-dioxide compound, its preparation method, and its applications. The general structural formula of the benzothiadiazine 1,1-dioxide compound is shown in Formula (I), or its isomers, or pharmaceutically acceptable salts, esters, or prodrugs thereof. The benzothiadiazine 1,1-dioxide compound of this invention has a novel structure, can selectively inhibit HDAC6 enzyme, has a strong protective effect on nerve cells, low toxicity, and low potential cardiotoxicity, and is expected to be used as a neuroprotective agent for the treatment of neurodegenerative diseases.

The application discloses an imiquimod prodrug and a preparation method and application thereof, and the structural formula of the imiquimod prodrug is shown in the following formula: the preparation method of the imiquimod prodrug comprises the following steps: step one, dissolving excessive imiquimod in anhydrous dioxane under a protective atmosphere, and dropping propargyl chloroformate dissolved in anhydrous dioxane under ice bath to obtain a mixture; step two, stirring the mixture obtained in the step one at 45-55 DEG C overnight; step three, filtering the product obtained in the step two, recovering excessive imiquimod, and purifying the filtrate after concentration and drying under reduced pressure to obtain the imiquimod prodrug. By using propargyloxy carbonyl to protect the amino group of the IMQ drug, the toxicity of the IMQ drug to cells is significantly reduced, and the systemic inflammatory response in mice is reduced; by using propargyloxy carbonyl to protect the amino group of the DOX drug, the toxicity of the DOX drug to cells is significantly reduced, and the cardiotoxicity in mice is reduced.